Hepatitis B flares in chronic hepatitis B: Pathogenesis, natural course, and management

Journal of Hepatology

Volumn 61, Issue 6, 2014, Pages 1407-1417

  Chang, Ming Ling ^a   Liaw, Yun Fan ^a  

^a CHANG GUNG UNIVERSITY COLLEGE OF MEDICINE   (Taiwan)

Author keywords

Alpha fetoprotein; Chemotherapy; Cirrhosis; Hepatitis B virus; Hepatocellular carcinoma; Immune clearance; Immune restoration; Interferona; Nucleos(t)ide analogue; Pregnancy

Indexed keywords

ALANINE AMINOTRANSFERASE; ALPHA FETOPROTEIN; ANTIVIRUS AGENT; CD20 ANTIBODY; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B(E) ANTIGEN; HLA ANTIGEN CLASS 1; INTERFERON; PEGINTERFERON; TUMOR NECROSIS FACTOR INHIBITOR; VIRUS DNA;

ACUTE HEPATITIS; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALPHA FETOPROTEIN BLOOD LEVEL; ANTIVIRAL THERAPY; CHEMOTHERAPY; CORTICOSTEROID THERAPY; CYTOLYSIS; CYTOTOXIC T LYMPHOCYTE; DECOMPENSATED LIVER CIRRHOSIS; DISEASE COURSE; DISEASE EXACERBATION; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; LABORATORY TEST; LIVER FAILURE; LIVER HISTOLOGY; MIXED INFECTION; MORTALITY; PATHOGENESIS; PREGNANT WOMAN; PRIORITY JOURNAL; REVIEW; TREATMENT OUTCOME; VIRAL CLEARANCE; VIREMIA; DISEASE MANAGEMENT; HEPATITIS B, CHRONIC; MASS SCREENING; METABOLISM; PATHOPHYSIOLOGY;

ALANINE TRANSAMINASE; ANTIVIRAL AGENTS; DISEASE MANAGEMENT; DISEASE PROGRESSION; DNA, VIRAL; HEPATITIS B; HEPATITIS B E ANTIGENS; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; MASS SCREENING;

EID: 84922716957     PISSN: 01688278     EISSN: 16000641     Source Type: Journal    
DOI: 10.1016/j.jhep.2014.08.033     Document Type: Review

References (96)

1. Y.F. Liaw, and C.M. Chu Hepatitis B virus infection Lancet 373 2009 582 592
2. R.P. Perrillo Acute flares in chronic hepatitis B: the natural and unnatural history of an immunologically mediated liver disease Gastroenterology 120 2001 1009 1022
3. Y.F. Liaw Hepatitis flares and hepatitis B e antigen seroconversion: implication in anti-hepatitis B virus therapy J Gastroenterol Hepatol 18 2003 246 252
4. Y.F. Liaw, C.M. Chu, I.J. Su, M.J. Huang, D.Y. Lin, and C.S. ChangChien Clinical and histological events preceding hepatitis B e antigen seroconversion in chronic type B hepatitis Gastroenterology 84 1983 216 219
5. A.S. Lok, and C.L. Lai Acute exacerbations in Chinese patients with chronic hepatitis B virus (HBV) infection. Incidence, predisposing factors and etiology J Hepatol 10 1990 29 34
6. A.S. Lok, and B.J. McMahon Practice Guidelines Committee, American Association for the Study of Liver Diseases. Chronic hepatitis B Hepatology 34 2001 1225 1241
7. Y.F. Liaw, and S.L. Tsai Pathogenesis and clinical significance of spontaneous exacerbation and remissions in chronic HBV infection Viral Hepat Rev 3 1997 143 154
8. Y.F. Liaw, S.S. Yang, T.J. Chen, and C.M. Chu Acute exacerbation in hepatitis B e antigen-positive chronic type B hepatitis: a clinicopathological study J Hepatol 1 1985 227 233
9. Y.F. Liaw, D.I. Tai, C.M. Chu, C.C. Pao, and T.J. Chen Acute exacerbation in chronic type B hepatitis: comparison between HBeAg and antibody positive patients Hepatology 7 1987 20 23
10. Y.S. Hsu, R.N. Chien, C.T. Yeh, I.S. Sheen, H.Y. Chiou, and C.M. Chu Long-term outcome after spontaneous HBeAg seroconversion in patients with chronic hepatitis B Hepatology 35 2002 1522 1527
11. F. Bonino, and M.R. Brunetto Chronic hepatitis B e antigen (HBeAg) negative, anti-HBe positive hepatitis B: an overview J Hepatol 39 2003 S160 S163
12. I.S. Sheen, Y.F. Liaw, D.I. Tai, and C.M. Chu Hepatic decompensation associated with hepatitis B e antigen clearance in chronic type B hepatitis Gastroenterology 89 1985 732 735
13. C.M. Chu, Y.F. Liaw, C.C. Pao, and M.J. Huang The etiology of acute hepatitis superimposed upon previously unrecognized asymptomatic HBsAg carriers Hepatology 9 1989 452 456
14. Y.F. Liaw, J.J. Chen, and T.J. Chen Acute exacerbation in patients with liver cirrhosis: a clinicopathological study Liver 10 1990 177 184
15. K. Koike, S. Iino, K. Kurai, K. Mitamura, Y. Endo, and H. Oka IgM anti-HBc in anti-HBe positive chronic type B hepatitis with acute exacerbations Hepatology 7 1987 573 576
16. Y.F. Liaw, D.Y. Tai, T.J. Chen, C.M. Chu, and M.J. Huang Alpha-fetoprotein changes in the course of chronic hepatitis: relation to bridging hepatic necrosis and hepatocellular carcinoma Liver 6 1986 133 137
17. Peng CY, Chen SH, Chu CM, Sheen IS, Tai DI, Tsai SL, et al. Oval cell activation during acute exacerbation in patients with chronic hepatitis type B or C. Asian Pacific Association for the Study of the Liver Meeting 2002;145-148.
18. Y.F. Liaw, C.C. Pao, C.M. Chu, I.S. Sheen, and M.J. Huang Changes of serum hepatitis B virus DNA in two types of clinical events preceding spontaneous hepatitis B e antigen seroconversion in chronic type B hepatitis Hepatology 7 1987 1 3
19. Y.F. Liaw, C.C. Pao, and C.M. Chu Changes of serum HBV DNA in relation to serum transaminase level during acute exacerbation in patients with chronic type B hepatitis Liver 8 1988 231 235
20. C.J. Liu, P.J. Chen, M.Y. Lai, J.H. Kao, C.F. Chang, and H.L. Wu A prospective study characterizing full-length hepatitis B virus genomes during acute exacerbation Gastroenterology 124 2003 80 90
21. T. Maruyama, S. Iino, K. Koike, K. Yasuda, and D.R. Milich Serology of acute exacerbation in chronic hepatitis B virus infection Gastroenterology 105 1993 1141 1151
22. C.M. Chu, and Y.F. Liaw Intrahepatic distribution of HBsAg and HBcAg in chronic hepatitis B virus infection: hepatocyte with cytoplasmic/membranous HBcAg as a possible target for immune hepatocytolysis Gastroenterology 92 1987 220 225
23. C.M. Chu, W.C. Shyu, R.W. Kuo, and Y.F. Liaw HLA class I antigen display on hepatocyte membrane in chronic hepatitis B virus infection: its role in the pathogenesis of chronic type B hepatitis Hepatology 8 1988 712 717
24. S.L. Tsai, P.J. Chen, M.Y. Lai, P.M. Yang, J.L. Sung, and J.H. Huang Acute exacerbations of chronic type B hepatitis are accompanied by increased T cell responses to hepatitis B core and e antigens. Implications for hepatitis B e antigen seroconversion J Clin Invest 89 1992 87 96
25. T. Takehara, N. Hayashi, K. Katayama, A. Kasahara, H. Fusamoto, and T. Kamada Hepatitis B core antigen-specific interferon gamma production of peripheral blood mononuclear cells during acute exacerbation of chronic hepatitis B Scand J Gastroenterol 27 1992 727 731
26. R. Fukuda, N. Ishimura, T.X. Nguyen, A. Chowdhury, S. Ishihara, and N. Kohge The expression of IL-2, IL-4 and interferon-gamma (IFN-gamma) mRNA using liver biopsies at different phases of acute exacerbation of chronic hepatitis B Clin Exp Immunol 100 1995 446 451
27. J.Y. Zhang, Z. Zhang, F. Lin, Z.S. Zou, R.N. Xu, and L. Jin Interleukin-17-producing CD4(+) T cells increase with severity of liver damage in patients with chronic hepatitis B Hepatology 51 2010 81 91
28. I.C. Feng, L.B. Koay, M.J. Sheu, H.T. Kuo, C.S. Sun, and C. Lee HBcAg-specific CD4+CD25+ regulatory T cells modulate immune tolerance and acute exacerbation on the natural history of chronic hepatitis B virus infection J Biomed Sci 14 2007 43 57
29. S.L. Tsai, S.L. Wang, I.C. Feng, H.T. Kuo, L.B. Koay, and M.J. Sheu Acute exacerbations of chronic hepatitis B are accompanied by decline of core antigen-specific regulatory T-cell frequencies: implications for successful anti-HBV treatments Hepat Monthly 7 2007 183 200
30. L.B. Koay, I.C. Feng, M.J. Sheu, H.T. Kuo, C.Y. Lin, and J.J. Chen Hepatitis B virus (HBV) core antigen-specific regulatory T cells confer sustained remission to anti-HBV therapy in chronic hepatitis B with acute exacerbation Hum Immunol 72 2011 687 698
31. A. Das, G. Ellis, C. Pallant, A.R. Lopes, P. Khanna, and D. Peppa IL-10-producing regulatory B cells in the pathogenesis of chronic hepatitis B virus infection J Immunol 189 2012 3925 3935
32. C. Dunn, M. Brunetto, G. Reynolds, T. Christophides, P.T. Kennedy, and P. Lampertico Cytokines induced during chronic hepatitis B virus infection promote a pathway for NK cell-mediated liver damage J Exp Med 204 2007 667 680
33. A.T. Tan, S. Koh, W. Goh, H.Y. Zhe, A.J. Gehring, and S.G. Lim A longitudinal analysis of innate and adaptive immune profile during hepatic flares in chronic hepatitis B J Hepatol 52 2010 330 339
34. Z. Wenjin, P. Chuanhui, W. Yunle, S.A. Lateef, and Z. Shusen Longitudinal fluctuations in PD1 and PD-L1 expression in association with changes in anti-viral immune response in chronic hepatitis B BMC Gastroenterol 12 2012 109
35. Y.F. Liaw, J.H. Kao, T. Piratvisuth, H.L.Y. Chan, R.N. Chien, and C.J. Liu Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2012 update Hepatol Int 6 2012 531 561
36. Y.F. Liaw Current trends in therapy for chronic viral hepatitis J Gastroenterol Hepatol 12 1997 S346 S353
37. M.F. Yuen, H.J. Yuan, C.K. Hui, D.K. Wong, W.M. Wong, and A.O. Chan A large population study of spontaneous HBeAg seroconversion and acute exacerbation of chronic hepatitis B infection: implications for antiviral therapy Gut 52 2003 416 419
38. M. Levrero, T. Pollicino, J. Petersen, L. Belloni, G. Raimondo, and M. Dandri Control of cccDNA function in hepatitis B virus infection J Hepatol 51 2009 581 592
39. C.M. Chu, and Y.F. Liaw Genotype C hepatitis B virus infection is associated with a higher risk of reactivation of hepatitis B and progression to cirrhosis than genotype B: a longitudinal study of hepatitis B e antigen-positive patients with normal aminotransferase levels at baseline J Hepatol 43 2005 411 417
40. M.F. Yuen, D.K. Wong, B.J. Zheng, C.C. Chan, J.C. Yuen, and B.C. Wong Difference in T helper responses during hepatitis flares in hepatitis B e antigen (HBeAg)-positive patients with genotypes B and C: implication for early HBeAg seroconversion J Viral Hepat 14 2007 269 275
41. W.J. Jeng, I.S. Sheen, and Y.F. Liaw Hepatitis B virus DNA level predicts hepatic decompensation in patients with acute exacerbation of chronic hepatitis B Clin Gastroenterol Hepatol 8 2010 541 545
42. Y.C. Chen, C.M. Chu, and Y.F. Liaw Age-specific prognosis following spontaneous hepatitis B e antigen seroconversion in chronic hepatitis B Hepatology 51 2010 435 444
43. Y.F. Liaw, D.I. Tai, C.M. Chu, and T.J. Chen The development of cirrhosis in patients with chronic type B hepatitis: a prospective study Hepatology 8 1988 493 496
44. S. Nair, and R.P. Perrillo Serum alanine aminotransferase flares during interferon treatment of chronic hepatitis B: is sustained clearance of HBV DNA dependent on levels of pretreatment viremia? Hepatology 34 2001 1021 1026
45. S. Rossol, G. Marinos, P. Carucci, M.V. Singer, R. Williams, and N.V. Naoumov Interleukin-12 induction of Th1 cytokines is important for viral clearance in chronic hepatitis B J Clin Invest 99 1997 3025 3033
46. G.K. Lau, T. Piratvisuth, K.X. Luo, P. Marcellin, S. Thongsawat, G. Cooksley Peginterferon Alfa-2a HBeAg-Positive Chronic Hepatitis B Study Group Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B N Engl J Med 352 2005 2682 2695
47. P. Marcellin, G.K. Lau, F. Bonino, P. Farci, S. Hadziyannis, R. Jin Peginterferon Alfa-2a HBeAg-Negative Chronic Hepatitis B Study Group Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B N Engl J Med 351 2004 1206 1217
48. H.J. Flink, D. Sprengers, B.E. Hansen, M. van Zonneveld, R.A. de Man, S.W. Schalm HBV 99-01 Study Group Flares in chronic hepatitis B patients induced by the host or the virus? Relation to treatment response during Peg-interferon {alpha}-2b therapy Gut 54 2005 1604 1609
49. W.G. Cooksley, T. Piratvisuth, S.D. Lee, V. Mahachai, Y.C. Chao, and T. Tanwandee Peginterferon alpha-2a (40 kDa): an advance in the treatment of hepatitis B e antigen-positive chronic hepatitis B J Viral Hepat 10 2003 298 305
50. L. Micco, D. Peppa, E. Loggi, A. Schurich, L. Jefferson, and C. Cursaro Differential boosting of innate and adaptive antiviral responses during pegylated-interferon-alpha therapy of chronic hepatitis B J Hepatol 58 2013 225 233
51. L. Belloni, L. Allweiss, F. Guerrieri, N. Pediconi, T. Volz, and T. Pollicino IFN-α inhibits HBV transcription and replication in cell culture and in humanized mice by targeting the epigenetic regulation of the nuclear cccDNA minichromosome J Clin Invest 122 2012 529 537
52. J. Lucifora, Y. Xia, F. Reisinger, K. Zhang, D. Stadler, and X. Cheng Specific and nonhepatotoxic degradation of nuclear hepatitis B virus cccDNA Science 343 2014 1221 1228
53. L. Allweiss, T. Volz, M. Lütgehetmann, K. Giersch, T. Bornscheuer, and A.W. Lohse Immune cell responses are not required to induce substantial hepatitis B virus antigen decline during pegylated interferon-alpha administration J Hepatol 60 2014 500 507
54. R.N. Chien, Y.F. Liaw, M. Atkins for Asian Hepatitis Lamivudine Trial Group Pretherapy alanine transaminase level as a determinant for hepatitis B e antigen seroconversion during lamivudine therapy in patients with chronic hepatitis B Hepatology 30 1999 770 774
55. Y.F. Liaw, N.W.Y. Leung, T.T. Chang, R. Guan, D.I. Tai, K.Y. Ng Asian hepatitis lamivudine study group Effects of extended lamivudine therapy in Asian patients with chronic hepatitis B Gastroenterology 119 2000 172 180
56. Y.F. Liaw, S.L. Tsai, R.N. Chien, C.T. Yeh, and C.M. Chu Prednisolone priming enhances Th1 response and efficacy of subsequent lamivudine therapy in patients with chronic hepatitis B Hepatology 32 2000 604 609
57. P. Marcellin, T.T. Chang, S.G. Lim, M.J. Tong, W. Sievert, M.L. Shiffman Adefovir Dipivoxil 437 Study Group Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B N Engl J Med 348 2003 808 816
58. S.J. Hadziyannis, N.C. Tassopoulos, E.J. Heathcote, T.T. Chang, G. Kitis, M. Rizzetto Adefovir Dipivoxil 438 Study Group Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B N Engl J Med 352 2005 2673 2681
59. T.T. Chang, R.G. Gish, R. de Man, A. Gadano, J. Sollano, Y.C. Chao BEHoLD AI463022 Study Group A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B N Engl J Med 354 2006 1001 1010
60. M. Zeng, Y. Mao, G. Yao, H. Wang, J. Hou, and Y. Wang A double-blind randomized trial of adefovir dipivoxil in Chinese subjects with HBeAg-positive chronic hepatitis B Hepatology 44 2006 108 116
61. C.L. Lai, D. Shouval, A.S. Lok, T.T. Chang, H. Cheinquer, Z. Goodman BEHoLD AI463027 Study Group Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B N Engl J Med 354 2006 1011 1020 Erratum in: N Engl J Med. 2006;354:1863
62. C.L. Lai, E. Gane, Y.F. Liaw, C.W. Hsu, S. Thongsawat, Y. Wang Globe Study Group Telbivudine versus lamivudine in patients with chronic hepatitis B N Engl J Med 357 2007 2576 2588
63. J. Hou, Y.K. Yin, D. Xu, D. Tan, J. Niu, and X. Zhou Telbivudine versus lamivudine in Chinese patients with chronic hepatitis B: results at 1 year of a randomized, double-blind trial Hepatology 47 2008 447 454
64. Y.F. Liaw, E. Gane, N. Leung, S. Zeuzem, Y. Wang, C.L. Lai The GLOBE Study Group 2-Year GLOBE trial results: telbivudine is superior to lamivudine in patients with chronic hepatitis B Gastroenterology 136 2009 486 495
65. P. Marcellin, E.J. Heathcote, M. Buti, E. Gane, R.A. de Man, and Z. Krastev Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B N Engl J Med 359 2008 2442 2455
66. C. Boni, A. Penna, A. Bertoletti, V. Lamonaca, I. Rapti, and G. Missale Transient restoration of anti-viral T cell responses induced by lamivudine therapy in chronic hepatitis B J Hepatol 39 2003 595 605 Erratum in: J Hepatol 2004;40:1053-1054
67. A. Evans, A. Riva, H. Cooksley, S. Phillips, S. Puranik, and A. Nathwani Programmed death 1 expression during antiviral treatment of chronic hepatitis B: impact of hepatitis B e-antigen seroconversion Hepatology 48 2008 759 769
68. Y.F. Liaw, R.N. Chien, C.T. Yeh, S.L. Tsai, and C.M. Chu Acute exacerbation and hepatitis B virus clearance after emergence of YMDD motif mutation during lamivudine therapy Hepatology 30 1999 567 572
69. Y.F. Liaw, R.N. Chien, and C.T. Yeh No benefit to continue lamivudine therapy after emergence of YMDD mutations Antivir Ther 9 2004 257 262
70. European Association for the Study of the Liver EASL clinical practice guidelines: management of chronic hepatitis B virus infection J Hepatol 57 2012 167 185
71. Y.F. Liaw Antiviral therapy of chronic hepatitis B: opportunities and challenges in Asia J Hepatol 51 2009 403 410
72. P. Honkoop, R.A. de Man, H.G. Niesters, P.E. Zondervan, and S.W. Schalm Acute exacerbation of chronic hepatitis B virus infection after withdrawal of lamivudine therapy Hepatology 32 2000 635 639
73. S.G. Lim, C.T. Wai, A. Rajnakova, T. Kajiji, and R. Guan Fatal hepatitis B reactivation following discontinuation of nucleoside analogues for chronic hepatitis B Gut 51 2002 597 599
74. W.J. Jeng, I.S. Sheen, Y.C. Chen, C.W. Hsu, R.N. Chien, and C.M. Chu Off therapy durability of response to Entecavir therapy in hepatitis B e antigen negative chronic hepatitis B patients Hepatology 58 2013 1888 1896
75. N.P. Zhang, J.G. Reijnders, M. Perquin, B.E. Hansen, and H.L. Janssen Frequency and clinical outcomes of flares related to nucleos(t)ide analogue therapy in patients with chronic hepatitis B J Viral Hepat 18 2011 e252 e257
76. B.C. Song, D.J. Suh, H.C. Lee, Y.H. Chung, and Y.S. Lee Hepatitis B e antigen seroconversion after lamivudine therapy is not durable in patients with chronic hepatitis B in Korea Hepatology 32 2000 803 806
77. R.N. Chien, C.T. Yeh, S.L. Tsai, C.M. Chu, and Y.F. Liaw The determinants for sustained HBeAg response to lamivudine therapy Hepatology 38 2003 1267 1273
78. H.W. Lee, H.J. Lee, J.S. Hwang, J.H. Sohn, J.Y. Jang, and K.J. Han Lamivudine maintenance beyond one year after HBeAg seroconversion is a major factor for sustained virologic response in HBeAg-positive chronic hepatitis B Hepatology 51 2010 415 421
79. S.J. Hadziyannis, V. Sevastianos, I. Rapti, D. Vassilopoulos, and E. Hadziyannis Sustained responses and loss of HBsAg in HBeAg-negative patients with chronic hepatitis B who stop long-term treatment with adefovir Gastroenterology 143 2012 629 636
80. J. Trowsdale, and A.G. Betz Mother's little helpers: mechanisms of maternal-fetal tolerance Nat Immunol 7 2006 241 246
81. M.J. ter Borg, W.F. Leemans, R.A. de Man, and H.L. Janssen Exacerbation of chronic hepatitis B infection after delivery J Viral Hepat 15 2008 37 41
82. V. Nguyen, P.K. Tan, A.J. Greenup, A. Glass, S. Davison, and D. Samarasinghe Anti-viral therapy for prevention of perinatal HBV transmission: extending therapy beyond birth does not protect against post-partum flare Aliment Pharmacol Ther 39 2014 1225 1234
83. H.H. Tan, H.F. Lui, and W.C. Chow Chronic hepatitis B virus (HBV) infection in pregnancy Hepatol Int 2 2008 370 375
84. A. Drake, A. Mijch, and J. Sasadeusz Immune reconstitution hepatitis in HIV and hepatitis B coinfection, despite lamivudine therapy as part of HAART Clin Infect Dis 39 2004 129 132
85. M. Crane, B. Oliver, G. Matthews, A. Avihingsanon, S. Ubolyam, and V. Markovska Immunopathogenesis of hepatic flare in HIV/hepatitis B virus (HBV)-coinfected individuals after the initiation of HBV-active antiretroviral therapy J Infect Dis 199 2009 974 981
86. J.C. Wu, S.D. Lee, P.F. Yeh, C.Y. Chan, Y.J. Wang, and Y.S. Huang Isoniazid-rifampin-induced hepatitis in hepatitis B carriers Gastroenterology 98 1990 502 504
87. A.S. Lok, R.H. Liang, E.K. Chiu, K.L. Wong, T.K. Chan, and D. Todd Reactivation of hepatitis B virus replication in patients receiving cytotoxic therapy. Report of a prospective study Gastroenterology 100 1991 182 188
88. G.K. Lau, M.L. He, D.Y. Fong, A. Bartholomeusz, W.Y. Au, and A.K. Lie Preemptive use of lamivudine reduces hepatitis B exacerbation after allogeneic hematopoietic cell transplantation Hepatology 36 2002 702 709
89. J.P. Hwang, and A.S. Lok Management of patients with hepatitis B who require immunosuppressive therapy Nat Rev Gastroenterol Hepatol 11 2014 209 219
90. J.W. Jang, J.Y. Choi, S.H. Bae, S.K. Yoon, U.I. Chang, and C.W. Kim A randomized controlled study of preemptive lamivudine in patients receiving transarterial chemo-lipiodolization Hepatology 43 2006 233 240
91. R. Loomba, A. Rowley, R. Wesley, T.J. Liang, J.H. Hoofnagle, and F. Pucino Systematic review: the effect of preventive lamivudine on hepatitis B reactivation during chemotherapy Ann Intern Med 148 2008 519 528
92. A.L. Cheng, C.A. Hsiung, I.J. Su, P.J. Chen, M.C. Chang, and C.J. Tsao Lymphoma Committee of Taiwan Cooperative Oncology Group. Steroid-free chemotherapy decreases risk of hepatitis B virus (HBV) reactivation in HBV-carriers with lymphoma Hepatology 37 2003 1320 1328
93. Y.H. Huang, L.T. Hsiao, Y.C. Hong, T.J. Chiou, Y.B. Yu, and J.P. Gau Randomized controlled trial of entecavir prophylaxis for rituximab-associated hepatitis B virus reactivation in patients with lymphoma and resolved hepatitis B J Clin Oncol 31 2013 2765 2772
94. C. Hsu, H.H. Tsou, S.J. Lin, M.C. Wang, M. Yao, W.L. Hwang on behalf of the Taiwan Cooperative Oncology Group Chemotherapy-induced hepatitis B reactivation in lymphoma patients with resolved HBV infection: a prospective study Hepatology 59 2014 2092 2100
95. R. Pérez-Alvarez, C. Díaz-Lagares, F. García-Hernández, L. Lopez-Roses, P. Brito-Zerón, M. Pérez-de-Lis BIOGEAS Study Group Hepatitis B virus (HBV) reactivation in patients receiving tumor necrosis factor (TNF)-targeted therapy: analysis of 257 cases Medicine 90 2011 359 371
96. A. Vallet-Pichard, H. Fontaine, V. Mallet, and S. Pol Viral hepatitis in solid organ transplantation other than liver J Hepatol 55 2011 474 482